Wegovy, a weight-loss drug, is launching in China with a significantly lower price than in the US, but patients will have to pay out of pocket.
While many patients in the US and Europe can rely on insurance for Wegovy, Chinese buyers are expected to handle costs themselves as it's not covered by national health insurance.
Novo is seeking to explore ways to make Wegovy more affordable for Chinese consumers, considering options like commercial insurance amid rising obesity rates.
China’s obesity rates are alarming, with estimates of around 85 million adults affected, and demand for weight-loss solutions like Wegovy is set to increase.
Collection
[
|
...
]